Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 8toripalimab 7darolutamide 7Drug Therapy 7Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Axitinib 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Cyclophosphamide 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × pemigatinib × Genitourinary × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡